Novel homing endonuclease

The novel I-Bma I endonuclease, derived from Bryopsis maxima, addresses the limitation of existing endonucleases by recognizing a unique 20-base sequence, enabling effective bacterial targeting and applications in genetic engineering and antibacterial agents.

WO2026234976A1PCT designated stage Publication Date: 2026-11-12TOHO UNIV FOUND
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2026/015710
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-04-20
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing homing endonucleases recognize relatively long sequences and are limited in their application for genetic engineering and gene analysis, necessitating the development of novel endonucleases with new recognition sequences.

Method used

A novel homing endonuclease, I-Bma I, is isolated from the chloroplast genes of the green alga Bryopsis maxima, capable of recognizing and cleaving a 20-base sequence including at least 15 consecutive bases, specifically atcggctaactccgtgccag, and is used to produce a gene encoding this enzyme, which can be expressed in vectors and transformed into host cells for production.

Benefits of technology

The I-Bma I endonuclease effectively targets and cleaves the rrn16S gene in bacteria, providing a basis for an antibacterial agent and enabling applications in genetic engineering and gene analysis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2026015710_12112026_PF_FP_ABST
    Figure JP2026015710_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention addresses the problem of providing a novel homing endonuclease having a new recognition sequence. The present invention provides a homing endonuclease comprising any of proteins (a) to (c). (a) A protein comprising an amino acid sequence represented by SEQ ID NO: 1; (b) a protein comprising an amino acid sequence in which one or more amino acids are added, deleted, or substituted in the amino acid sequence represented by SEQ ID NO: 1 and having activity of recognizing and cleaving a nucleotide sequence of 20 nucleotides including a nucleotide sequence of at least 15 consecutive nucleotides in the nucleotide sequence of atcggctaactccgtgccag (SEQ ID NO: 3); and (c) a protein comprising an amino acid sequence having 90% or more sequence identity to the amino acid sequence represented by SEQ ID NO: 1 and having activity of recognizing and cleaving a nucleotide sequence of 20 nucleotides including a nucleotide sequence of at least 15 consecutive nucleotides in the nucleotide sequence of atcggctaactccgtgccag (SEQ ID NO: 3).
Need to check novelty before this filing date? Find Prior Art

Description

Novel Homing Endonuclease

[0001] The present invention relates to a novel nuclease that cleaves DNA double strands. More specifically, the present invention relates to a novel homing endonuclease involved in the horizontal transfer of mobile introns, a gene encoding said homing endonuclease, and uses of said homing endonuclease.

[0002] Endonucleases are a class of nucleases (nucleolytic enzymes) that hydrolyze phosphodiester bonds within a polynucleotide chain. Among endonucleases, restriction enzymes that recognize relatively short sequences of several bases and cleave double-stranded DNA within or near such sequences are enzymes indispensable for gene cloning and analysis.

[0003] As one type of endonuclease, homing endonuclease (HE) is known. Homing endonucleases are endonucleases encoded within mobile genetic elements (mobile introns) that propagate horizontally between genomes. The horizontal propagation of mobile introns is initiated when a homing endonuclease recognizes a specific sequence on the genome and induces a DNA double-strand break (DSB) (Non-Patent Document 1, etc.).

[0004] Most homing endonucleases are known to recognize relatively long recognition sequences of 20 or more bases and specifically cleave DNA double strands. For example, homing endonuclease-like proteins have been found in the chloroplast genomes of green algae, and to date, I-CreI derived from the green alga Chlamydomonas reinhardtii with the recognition sequence "CTGGGTTCAAAACGTCGTGAGACAG" (Non-Patent Document 2), CpaII derived from the green alga Chlamydomonas pallidostigmatica with the recognition sequence "CCCGGCTAACTCTGTGCCAG" (Non-Patent Document 3), and the like have been reported.

[0005] Homing endonucleases are used to obtain large DNA fragments or to selectively damage genomic DNA (Patent Document 1). Therefore, novel endonucleases with new recognition sequences are important for the further advancement and expansion of genetic engineering and gene application technologies.

[0006] Japanese Patent Publication No. 2023-126653

[0007] Stoddard BL., "Homing endonuclease structure and function,"Q Rev Biophys. 2005 Feb; 38 (1):49-95. Epub 2005 Dec 9.Jingshan Wang, Hyong-Ha Kim, Xiaoqin Yuan and David L. Herrin, "Purification, biochemical characterization and protein-DNA interactions of the I-CreI endonuclease produced in Escherichia coli" Nucleic Acids Research, 1997, 25, 19, 3767-3776Monique Turmel, Jean-Patrick Mercier, Vincent Cote, Christian Otis and Claude Lemieux, "The site-specific DNA endonuclease encoded by a group I intron in the Chlamydomonas pallidostigmatica chloroplast small subunit rRNA gene introduces a single-strand break at low concentrations of Mg2+." Nucleic Acid Research, 1995, 23, 13, 2519-2525

[0008] The present invention aims to provide a novel homing endonuclease having a new recognition sequence.

[0009] As a result of diligent research to solve the above problems, the inventors of this invention succeeded in isolating a homing endonuclease that can specifically cleave double-stranded DNA at a novel cleavage site within the intron of the ribosomal RNA small subunit (rrn16S) gene while studying the chloroplast genes of the green alga Bryopsis maxima, thus completing the present invention.

[0010] In other words, the present invention encompasses the following: [1] A homing endonuclease comprising any of the following proteins (a) to (c): (a) A protein comprising the amino acid sequence shown in SEQ ID NO: 1 (b) A protein comprising an amino acid sequence in which one or more amino acids are added, deleted, or substituted in the amino acid sequence shown in SEQ ID NO: 1, and having the activity to recognize and cleave a 20-base sequence including at least 15 consecutive bases in the base sequence: atcggctaactccgtgccag (SEQ ID NO: 3) (c) A protein comprising an amino acid sequence having 90% or more sequence identity with the amino acid sequence shown in SEQ ID NO: 1, and having the activity to recognize and cleave a 20-base sequence including at least 15 consecutive bases in the base sequence: atcggctaactccgtgccag (SEQ ID NO: 3) [2] A gene encoding the homing endonuclease described in [1]. [3] A gene encoding a homing endonuclease comprising any of the following polynucleotides (d) to (f). (d) A polynucleotide comprising the base sequence shown in SEQ ID NO: 2. (e) A polynucleotide comprising a base sequence having 90% or more sequence identity with the base sequence shown in SEQ ID NO: 2, and encoding a protein having the activity to recognize and cleave a 20-base sequence including at least 15 consecutive bases in the base sequence: atcggctaactccgtgccag (SEQ ID NO: 3). (f) A polynucleotide that hybridizes under stringent conditions with a base sequence complementary to the base sequence shown in SEQ ID NO: 2, and encoding a protein having the activity to recognize and cleave a 20-base sequence including at least 15 consecutive bases in the base sequence: atcggctaactccgtgccag (SEQ ID NO: 3). A vector comprising the gene described in [4], [2], or [3]. [5] The vector according to [4], wherein the vector is a plasmid or a bacteriophage. [6] A transformant comprising the vector described in [4]. [7] A method for producing a homing endonuclease, characterized by culturing the transformant described in [6] and collecting the protein described in [1] from the resulting culture. An antibacterial agent containing the homing endonuclease described in [8] [1] as an active ingredient.[9] The antimicrobial agent described in [8], in the form of a bacteriophage formulation. This application claims priority to Japanese Patent Application No. 2025-078725, filed on 9 May 2025, and includes the contents described in the specification of said patent application.

[0011] The present invention provides a novel homing endonuclease having a new recognition sequence, a gene encoding the homing endonuclease, and a method for producing the homing endonuclease. The homing endonuclease of the present invention is useful as an antimicrobial agent because it can recognize and cleave a 20-base sequence in the rrn16S gene, which is commonly found in bacteria.

[0012] Figure 1 shows the results of a cleavage test of substrate S1 (pMD20::orf14_subst0[620rc;741R]) by an endonuclease protein (gel electrophoresis images of the cleavage fragments) (M: molecular weight marker, lane 1: substrate S1 and I-Bma I protein (P1), lane 2: substrate S1 and DHFR protein (C1), lane 3: substrate S1 (before cleavage), lane 4: I-Bma I protein (P1), lane 5: DHFR protein (C1)). Figure 2 shows the results of a cleavage test of substrate S1044 (pMD20::orf14_subst0[420rc..741R]_ds64) by an endonuclease protein (gel electrophoresis images of the cleavage fragments) (M: molecular weight marker, lane 1: substrate S1044 and I-Bma I protein (P1), lane 2: substrate S1044 and Eco RI). Figure 3 shows the sequence analysis results for gel X400 (X2). Figure 4 shows the waveform data of the sequence analysis for gel X400 (X2). Figure 5 shows the sequence analysis results for gel X600 (X1). Figure 6 shows the waveform data of the sequence analysis for gel X600 (X1). Figure 7 shows the nucleotide sequence of the complementary strand of the basic target substrate (orf14_subst0) and the nucleotide sequence of the DNA fragment extracted from gel X600 (X1). Figure 8A shows the nucleotide sequence of the DNA fragment (X2 (M13R->)) extracted from gel X400 and the nucleotide sequence of the DNA fragment (X1 (<-264R)) extracted from gel X600. Figure 8B shows the cleavage site (arrow) and cleavage shape (underlined portion is the overhang portion of the cleaved fragment) of the basic target substrate (orf14_subst0) by the I-Bma I protein. Figure 9 shows the site and nucleotide sequence of the narrowed-down target substrate (orf14_subst0_ds20) in orf14_subst0. Figure 10 shows the results of the cleavage test of substrate S20 (pMD20 [620rc; 741R]_ds20) by I-Bma I protein (gel electrophoresis images of the cleavage fragments) (M: molecular weight marker, lane 1: substrate S20 and I-Bma I protein (P1), lane 2: I-Bma I protein (P1), lane 3: substrate S20).Figure 11 shows the results of a cleavage test of substrate S2 (Ecoli_rrn16S [17..1313]) by I-Bma I protein (gel electrophoresis images of the cleavage fragments) (M: molecular weight marker, lane 1: substrate S2 and I-Bma I protein (P1), lane 2: I-Bma I protein (P1)).

[0013] The present invention will be described in detail below.

[0014] 1. Homing endonuclease and gene encoding homing endonuclease The homing endonuclease of the present invention has the following formula in double-stranded DNA: It has the activity to recognize the base sequence represented by the arrow and cleave it at the position indicated by the arrow.

[0015] The nucleotide sequence recognized by the homing endonuclease of the present invention only needs to include at least 15 consecutive nucleotide sequences containing the cleavage site from the nucleotide sequence of the main strand of the double-stranded DNA (SEQ ID NO: 3) and the nucleotide sequence of its complementary strand, and some of the 20 nucleotides may be substituted with other nucleotides.

[0016] In the present invention, "recognize and cleave" means that the homing endonuclease has the function of binding to the site having the 20-base recognition sequence and cleaving the inside of the 20-base pair.

[0017] The novel endonuclease of the present invention (which may be referred to as "I-Bma I protein" herein) includes a homing endonuclease comprising any of the following proteins (a) to (c).

[0018] (a) A protein consisting of the amino acid sequence shown in SEQ ID NO: 1; (b) A protein consisting of an amino acid sequence in which one or more amino acids are added, deleted, or substituted in the amino acid sequence shown in SEQ ID NO: 1, and which has the activity to recognize and cleave a 20-base sequence including at least 15 consecutive bases in the base sequence: atcggctaactccgtgccag (SEQ ID NO: 3); (c) A protein consisting of an amino acid sequence having 90% or more sequence identity with the amino acid sequence shown in SEQ ID NO: 1, and which has the activity to recognize and cleave a 20-base sequence including at least 15 consecutive bases in the base sequence: atcggctaactccgtgccag (SEQ ID NO: 3).

[0019] With respect to (b) above, the range of "one to several" in "an amino acid sequence in which one or several amino acids are added, deleted, or substituted in the amino acid sequence shown in SEQ ID NO: 1" is not particularly limited in number, as long as the protein consisting of the amino acid sequence shown in SEQ ID NO: 1 has the activity to recognize and cleave the target sequence, but for example, it means about 1 to 10, preferably 1 to 7, more preferably 1 to 5, and even more preferably 1 to 3. Deletion of an amino acid means selecting and deleting any amino acid from the amino acid sequence shown in SEQ ID NO: 1. Addition of an amino acid means adding one to several amino acids to the N-terminus or C-terminus of the amino acid sequence shown in SEQ ID NO: 1. Examples of amino acid substitutions include conservative amino acid substitutions.

[0020] The above-mentioned conservative amino acid substitutions refer to substitutions between amino acids with similar properties, such as polarity, electrical properties, and structural properties, including hydrophobic amino acids, polar amino acids, acidic amino acids, basic amino acids, amino acids with branched side chains, and aromatic amino acids. Examples of hydrophobic (nonpolar) amino acids include glycine, alanine, valine, leucine, isoleucine, and proline; examples of polar amino acids include serine, threonine, cysteine, methionine, asparagine, and glutamine; examples of acidic amino acids include aspartic acid and glutamic acid; examples of basic amino acids include lysine, arginine, and histidine; examples of amino acids with branched side chains include valine, isoleucine, and leucine; and examples of aromatic amino acids include phenylalanine, tyrosine, tryptophan, and histidine. Preferred conservative amino acid substitutions include substitutions between amino acids selected from valine, leucine, and isoleucine, phenylalanine and tyrosine, lysine and arginine, alanine and valine, and asparagine and glutamine.

[0021] Amino acid addition, deletion, or substitution can be performed by modifying the gene encoding the protein consisting of the amino acid sequence described in Sequence ID No. 1 using methods known in the art. Mutations can be introduced into the gene using known methods such as the Kunkel method or the Gapped duplex method, or similar methods.

[0022] With respect to (c) above, "an amino acid sequence having 90% or more sequence identity" means that the sequence identity of the amino acid sequence is at least 90%, preferably 95% or more, more preferably 97% or more, and most preferably 98% or more. The sequence identity of amino acids can be determined using methods well known to those skilled in the art, sequence analysis software, etc. Examples include the blastp program of the BLAST algorithm and the fasta program of the FASTA algorithm. Here, the sequence identity of the amino acid sequence is a value expressed as a percentage of the frequency at which the same amino acid appears in the same location when the amino acid sequence to be evaluated is compared with the amino acid sequence shown in Sequence ID No. 1.

[0023] In (b) and (c) above, "having the activity to recognize and cleave the base sequence: atcggctaactccgtgccag (SEQ ID NO: 3)" means that it is substantially equivalent to the activity held by a protein consisting of the amino acid sequence described in SEQ ID NO: 1.

[0024] The present invention also provides a gene encoding the above-mentioned homing endonuclease. Specific examples of such genes include a gene encoding a homing endonuclease consisting of any of the following polynucleotides (which may be referred to herein as the "I-Bma I gene" or the "orf14 gene"): (d) a polynucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 2; (e) a polynucleotide encoding a protein having a nucleotide sequence having 90% or more sequence identity with the nucleotide sequence shown in SEQ ID NO: 2, and having the activity to recognize and cleave a 20-nucleotide sequence including at least 15 consecutive nucleotides in the nucleotide sequence: atcggctaactccgtgccag (SEQ ID NO: 3); (f) a polynucleotide that hybridizes under stringent conditions with a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 2, and has the activity to recognize and cleave a 20-nucleotide sequence including at least 15 consecutive nucleotides in the nucleotide sequence: atcggctaactccgtgccag (SEQ ID NO: 3).

[0025] With respect to (e) above, "a nucleotide sequence having 90% or more sequence identity" means that the sequence identity of the nucleotide sequence is at least 90%, preferably 95% or more, more preferably 97% or more, and most preferably 98% or more. The sequence identity of a nucleotide sequence can be determined using methods well known to those skilled in the art, sequence analysis software, etc. Examples include the blastn program of the BLAST algorithm and the fasta program of the FASTA algorithm. Here, the sequence identity of a nucleotide sequence is a value expressed as a percentage of the frequency at which the same nucleotide appears in the same location when the nucleotide sequence to be evaluated is compared with the nucleotide sequence described in Sequence ID No. 2.

[0026] With respect to (f) above, "stringent conditions" means conditions under which so-called specific hybrids are formed and nonspecific hybrids are not formed, and can be appropriately determined by referring to, for example, Green and Sambrook, Molecular Cloning, 4th Ed (2012), Cold Spring Harbor Laboratory Press. Specifically, stringent conditions can be set by the temperature and salt concentration in the solution during Southern hybridization, and the temperature and salt concentration in the solution during the washing step of Southern hybridization. More specifically, for example, conditions in which the reaction temperature of hybridization is in the range of 25 to 70°C, preferably 50 to 70°C, more preferably 55 to 68°C, and / or conditions in which the formamide concentration in the hybridization solution is in the range of 0 to 50%, preferably 20 to 50%, more preferably 35 to 45%. Furthermore, the sodium salt concentration during the washing of the filter after hybridization is 15 to 750 mM, preferably 15 to 500 mM, more preferably 15 to 300 mM, 15 to 200 mM, or 15 to 100 mM.

[0027] The method for obtaining the I-Bma I gene is not particularly limited. For example, it can be directly isolated from the chloroplast DNA of the green alga Bryopsis maxima using known methods, or the target DNA or cDNA can be isolated using probe DNA prepared based on the base sequence of Sequence ID No. 2. The obtained DNA or cDNA can be amplified by conventional gene amplification methods such as PCR, NASBN, or TMA. Furthermore, cDNA can also be obtained by RT-PCR using a primer set prepared based on the base sequence of Sequence ID No. 2 and mRNA isolated from the chloroplast of the green alga Bryopsis maxima as a template.

[0028] 2. Method for producing vectors, transformants, and homing endonucleases The I-Bma I gene of the present invention can be used by inserting it into a suitable vector. The type of vector used in the present invention is not particularly limited, and may be, for example, one that can replicate autonomously in host cells, or one that, when introduced into host cells, is incorporated into the genome of the host cell and replicates together with the incorporated chromosome. Examples include plasmids, bacteriophages, and viral vectors. More specifically, examples of plasmids include plasmids derived from Escherichia coli (pBR322, pBR325, pUC12, pUC13, etc.), plasmids derived from Bacillus subtilis (pUB110, pTP5, pC194, etc.), and plasmids derived from yeast (pSH19, pSH15, etc.). Examples of bacteriophages include lambda phages (Charon4A, Charon21A, EMBL3, EMBL4, λgt100, gt11, zap), ψX174, M13mp18, and M13mp19. Examples of viruses from which viral vectors are derived include adenoviruses, adeno-associated viruses, lentiviruses, vaccinia viruses, baculoviruses, and retroviruses.

[0029] The above vector can be appropriately selected and used if it is suitable for the host cell into which it will be introduced. The vector also contains a polynucleotide containing a gene encoding the I-Bma I protein operably linked to an appropriate promoter, and preferably includes a transcription termination signal, i.e., a terminator region, downstream of the polynucleotide. Furthermore, it may also include selection marker genes for selecting transformed cells (e.g., drug resistance genes, genes that complement nutrient requirement mutations). It may also include sequences encoding tag sequences useful for the isolation and purification of expressed proteins. The insertion site of the gene in the vector can be anywhere in a region not involved in the replication of the recombinant vector, and usually a multi-cloning site within the vector is used.

[0030] The transformants of the present invention can be produced by introducing a vector (recombinant vector) into which the above-mentioned I-Bma I gene has been introduced into a suitable host cell. The introduction of the vector into host cells can be carried out by known transformation methods such as the competent cell method, protoplast method, calcium phosphate coprecipitation method, bacteriophage infection method, viral infection method, and Agrobacterium method.

[0031] Any cell that can express the above vector can be used as the host cell to which the vector is introduced and used for the expression of recombinant protein. Commonly used known microorganisms such as bacteria, yeast, fungi, and mammalian cells can be used. Specifically, examples include bacteria belonging to the Escherichia genus such as Escherichia coli, the Bacillus genus such as Bacillus subtilis, the Pseudomonas genus such as Pseudomonas putida, and the Rhizobium genus such as Rhizobium meliloti; yeasts such as Saccharomyces cerevisiae and Schizosaccharomyces pombe; animal cells such as COS cells and CHO cells; and insect cells such as Sf9 and Sf21. Recombinant cells can be cultured by methods known to the host cell that are suitable for the host cell.

[0032] The homing endonuclease of the present invention can be obtained by culturing the above-mentioned transformant and collecting it from the culture. "Culture" means either the culture supernatant, cultured cells or cultured bacterial cells, or lysates of cells or bacterial cells. The method for culturing the transformant of the present invention is carried out according to the usual method used for culturing the host. As the culture medium for culturing the transformant obtained using microorganisms such as Escherichia coli as a host, either a natural medium or a synthetic medium may be used, as long as it contains a carbon source, nitrogen source, inorganic salts, etc. that the microorganism can assimilate and can efficiently culture the transformant.

[0033] As carbon sources, carbohydrates such as glucose, fructose, sucrose, and starch; organic acids such as acetic acid and propionic acid; and alcohols such as ethanol and propanol are used. As nitrogen sources, inorganic acids such as ammonia, ammonium chloride, ammonium sulfate, ammonium acetate, and ammonium phosphate, or ammonium salts of organic acids, or other nitrogen-containing compounds are used, as well as peptone, meat extract, and corn steep liquor. As inorganic substances, monopotassium phosphate, dipotassium phosphate, magnesium phosphate, magnesium sulfate, sodium chloride, ferrous sulfate, manganese sulfate, copper sulfate, and calcium carbonate are used.

[0034] Transformants obtained using bacteria as a host are usually cultured for 12 to 18 hours under aerobic conditions such as shaking culture or aerated stirring culture at a culture temperature suitable for growth. During the culture period, the pH is maintained at 6.5 to 7.5, preferably 7.0. pH adjustment is performed using inorganic or organic acids, alkaline solutions, etc. Antibiotics (kanamycin, ampicillin, tetracycline, etc.) may be added to the culture medium as needed during culture. When culturing microorganisms transformed with an expression vector using an inducible promoter, an inducer may be added to the culture medium as needed. For example, when culturing microorganisms transformed with an expression vector using a Lac promoter, isopropyl-β-D-thiogalactoside (IPTG) may be added to the culture medium, and when culturing microorganisms transformed with an expression vector using a trp promoter, indoleacetic acid (IAA) may be added to the culture medium. As a culture medium for transformants obtained using animal cells as a host, commonly used RPMI1640 medium, DMEM medium, or these media supplemented with fetal bovine serum, etc., are used.

[0035] Culturing is usually carried out for 1 to 3 days at a culture temperature suitable for growth (20°C to 37°C). Antibiotics may be added to the culture medium as needed during cultivation. After culturing, if the I-Bma I protein of the present invention is produced inside or within the bacterial cells, I-Bma I is extracted by disrupting the bacterial cells or cells. If the I-Bma I protein of the present invention is produced outside the bacterial cells or cells, the culture medium can be used as is, or the bacterial cells or cells can be removed by centrifugation or the like. Subsequently, the homing endonuclease of the present invention can be isolated and purified from the culture by using general biochemical methods used for protein isolation and purification, such as ammonium sulfate precipitation, gel chromatography, ion exchange chromatography, affinity chromatography, etc., either alone or in appropriate combinations.

[0036] 3. Uses of Homing Endonuclease The rrn16S gene of prokaryotes (Bacteria) has a nucleotide sequence that has 100% or extremely high sequence identity with the recognition sequence that the homing endonuclease of the present invention can recognize and cleave. Therefore, the homing endonuclease of the present invention can be used as an antibacterial agent containing it as an active ingredient.

[0037] The rrn16S gene of E. coli contains the recognition sequence of the homing endonuclease of the present invention (SEQ ID NO: 3) and a sequence that differs by only one nucleotide (5'-accggctaactccgtgccag-3': SEQ ID NO: 4). Using the nucleotide sequence of SEQ ID NO: 4 (E. coli_rrn16S_ds20) as the search sequence, a homology search was performed using NCBI BLAST as the search tool (with the search option specified as "organism"), and the results are shown in Table 1 below.

[0038]

[0039] As shown in Table 1, the above bacterial genera have 100% or at least 90% homology to the recognition sequence (20 bases) in the rrn16S gene of Escherichia coli (E. coli). Furthermore, as shown in the examples below, it has been confirmed that the recognition sequence (20 bases) in the rrn16S sequence of Escherichia coli (E. coli) is degraded by the homing endonuclease (I-Bma I) of the present invention. Therefore, the bacterial genera targeted by the antibacterial agent of the present invention are not particularly limited as long as they have the above-mentioned recognition sequence or homologous sequence thereof, but for example, the genera Escherichia, Shigella, Salmonella, Proteus, Yersinia, Serratia, Enterobacter, Vibrio, Aeromonas, Haemophilus, Pseudomonas, Burkholderia, Legionella, and Neisseria shown in Table 1. Examples of bacteria include those belonging to the genera Neisseria, Staphylococcus, Streptococcus, Enterococcus, Bacillus, Clostridium, Lactobacillus, Listeria, Mycobacterium, Mycoplasma, Campylobacter, Helicobacter, Treponema, and Rickettsia.

[0040] The antibacterial agent of the present invention can be provided in the form of various compositions such as pharmaceuticals, food and beverages, and feeds. When the antibacterial agent of the present invention is incorporated into a pharmaceutical, it is mixed with pharmacologically and pharmaceutically acceptable additives, and the homing endonuclease is used alone or mixed with pharmacologically and pharmaceutically acceptable additives, and can be formulated into various preparations such as tablets, powders, granules, fine granules, capsules, oral liquids (suspensions, syrups, emulsions, etc.), external liquids (injections, gargles and mouth washes, sprays and aerosols, inhalants, liniments, etc.), ointments, injections, infusions, suppositories and the like by methods known in the art. The pharmacologically and pharmaceutically acceptable additives are appropriately selected according to the dosage form and application, including pharmaceutical base materials and carriers, excipients, diluents, binders, lubricants, coating agents, disintegrants or disintegration aids, stabilizers, preservatives, antiseptics, bulking agents, dispersants, wetting agents, buffers, solubilizers or solubilizing aids, isotonic agents, pH adjusters, propellants, coloring agents, sweetening agents, flavoring agents, perfumes and the like, which can be appropriately added to prepare various preparation forms that can be orally or parenterally administered systemically or topically by various known methods. When the pharmaceutical of the present invention is provided in each of the above forms, it can be produced by a production method commonly used by those skilled in the art, for example, the production method shown in the General Rules for Preparations [2] Individual Monographs for Preparations of the Japanese Pharmacopoeia. The pharmaceutical of the present invention prepared into various preparation forms can be orally or parenterally administered systemically or topically. When the pharmaceutical of the present invention is orally administered, it can be formulated into tablets, capsules, granules, powders, pills, oral solutions, suspensions, emulsions, syrups and the like, or can be made into a dry product to be redissolved at the time of use. When the pharmaceutical of the present invention is parenterally administered, it is formulated into intravenous injections (including infusions), intramuscular injections, intraperitoneal injections, subcutaneous injections, suppositories and the like, and in the case of injectable preparations, it is provided in the form of unit dose ampoules or multi-dose containers.

[0041] As one embodiment where the antibacterial agent of the present invention is used as a pharmaceutical, it is preferably in the form of a bacteriophage preparation into which the I-Bma I gene has been introduced, and is used for phage therapy to treat infectious diseases caused by the aforementioned bacteria. The bacteriophage preparation can be prepared using a suitable pharmaceutically acceptable carrier together with the bacteriophage. For example, as carriers and diluents when used as liquid preparations such as injections, there may be mentioned buffer solutions such as phosphate buffer, aqueous media such as physiological saline and distilled water, and injectable non-aqueous media such as polyethylene glycol, propylene glycol, and ethyl oleate. In addition, the bacteriophage preparation may contain stabilizers, isotonic agents, chelating agents, pH adjusters, surfactants, preservatives, antioxidants and the like.

[0042] When the antibacterial agent of the present invention is used as a medicament for preventing and / or treating the aforementioned bacterial infectious diseases, it can be safely administered parenterally or orally to mammals such as humans, cattle, horses, dogs, cats, mice, rats, and rabbits. The dosage of the pharmaceutical product of the present invention should be appropriately selected in consideration of the specific dosage form, the type of target disease, symptoms and the like, and is not particularly limited.

[0043] When the antibacterial agent of the present invention is incorporated into foods and beverages, additives commonly used according to the type of the food or beverage may be appropriately mixed with the homing endonuclease to form an edible form, for example, solid, liquid, granular, particulate, powdery, capsule, cream, or paste form. As the additive, any additive that is permissible under the Food Sanitation Act can be used, and examples thereof include sweeteners such as glucose, sucrose, fructose, isomerized liquid sugar, aspartame, and stevia; acidulants such as citric acid, malic acid, and tartaric acid; excipients such as dextrin and starch; binders, diluents, flavors, coloring agents, buffers, thickeners, gelling agents, stabilizers, preservatives, emulsifiers, dispersants, suspending agents, antiseptics and the like.

[0044] Furthermore, the antibacterial agent of the present invention may be added to feed as a feed additive. In addition to the homing endonuclease described above, the feed of the present invention may also contain other ingredients commonly used in conventional compound feeds, depending on the type of animal, developmental stage, region, and other breeding environment factors. Examples of such ingredients include grains or processed grains (corn, milo, barley, etc.), brans (wheat bran, rice bran, corn gluten feed, etc.), vegetable oilseed meals (soybean oilseed meal, sesame oilseed meal, cottonseed oilseed meal, etc.), animal-derived ingredients (skim milk powder, fish meal, meat and bone meal, etc.), minerals (calcium carbonate, calcium phosphate, salt, anhydrous silicic acid, etc.), vitamins, amino acids, yeasts such as brewer's yeast, and fine powders of inorganic substances (crystalline cellulose, talc, silica, etc.).

[0045] The present invention will be described in more detail below with reference to examples. However, these examples are not intended to limit the present invention.

[0046] (Example 1) Isolation and purification of the I-Bma I(orf14) gene The green alga Bryopsis maxima was collected from Choshi Beach, Chiba Prefecture, Japan. The thallus of Bryopsis maxima was mechanically cut and the internal cell sap was squeezed out, and the cell sap was centrifuged to obtain the chloroplast fraction. The obtained chloroplast fraction was crushed and purified to obtain chloroplast genomic DNA.

[0047] The obtained chloroplast genomic DNA of *Aquila japonica* was analyzed, and its entire base sequence was determined using a standard shotgun method. The *Aquila japonica* chloroplast genome was a circular double-stranded DNA with a length of approximately 143 kilobases.

[0048] By comparing the complete nucleotide sequence data of the chloroplast genome DNA of *Anemarrhena aspergillus* obtained above with the nucleotide sequence data of the ribosomal RNA small subunit (rrn16S) gene of chloroplast genomes of known algae registered in the US NCBI database, the nucleotide sequence of the rrn16S gene in *Anemarrhena aspergillus* chloroplast DNA was identified. The nucleotide sequence of this rrn16S gene is a 3334-base pair sequence, containing an intron, and it was suggested that a nucleotide sequence encoding a type of protein called a homing endonuclease (HE) exists within one of these introns. Referring to the start and end of the nucleotide sequence encoding this HE-type protein, an start oligonucleotide (ORF14F) containing the start codon and a stop oligonucleotide (ORF14R) containing the stop codon were constructed. Using the prepared ORF14F and ORF14R as PCR primer pairs, PCR amplification was performed using Aquilegia chloroplast DNA as a template (conditions: 94°C for 2 minutes, (98°C for 10 seconds, 55°C for 10 seconds, 68°C for 30 seconds) x 25 cycles, 68°C for 4 minutes). The target homing endonuclease (HE) gene (I-Bma I (orf14) gene) (SEQ ID NO: 2), with a length of 630 bases, was isolated, and the protein encoded by this gene was named "I-Bma I" (SEQ ID NO: 1).

[0049] Start oligonucleotide (ORF14F): 5'-CATATGAATATTACATCTGAACAAAATGC-3' (SEQ ID NO: 5) Stop oligonucleotide (ORF14R): 5'-CTCGAGGTCGTTACGGGATTTACCAGG-3' (SEQ ID NO: 6)

[0050] (Example 2) Evaluation test of I-Bma I cleavage activity (1) (1) Preparation of enzyme protein Using the pET24a plasmid (pET24a::orf14) into which the I-Bma I (orf14) gene was inserted, I-Bma I protein (P1) was prepared using a cell-free protein synthesis kit (BioLabs PURExpress In Vitro Protein Synthesis Kit (E6800S)). As a positive control template DNA, DHFR protein (C1) was prepared using a plasmid containing the Dihydroflorate reductase (DHFR) gene included in the kit.

[0051] (2) Preparation of Substrate S1 (pMD20::orf14_subst0[620rc;741R]) Substrate S1 (pMD20::orf14_subst0[620rc;741R]) was prepared as a substrate. Substrate S1 was prepared by inserting orf14_subst0 (tgacggtact taaggaataa gcatcggcta actccgtgcc agcagccgcg gtaatacgga ggat (SEQ ID NO: 7), a 64 bp basic substrate of I-Bma I, into a pMD20 vector, and then PCR amplifying the same vector using the following primer pair [620rc;741R] (conditions: 94°C for 2 minutes, (98°C for 10 seconds, 55°C for 10 seconds, 68°C for 30 seconds) x 25 cycles, 68°C for 4 minutes). Substrate S1 was a linear double-stranded DNA with a length of 1264 bp.

[0052] Primer pair [620rc;741R] 620rc: 5'-GCCACCTCTGACTTGAGCGTC-3' (SEQ ID NO: 8) 741R: 5'-CACGGAAATGTTGAATACTCATACTCTTCC-3' (SEQ ID NO: 9)

[0053] (3) Reaction of enzyme protein with substrate S1 The P1(I-Bma I) prepared in (1) and (2) respectively was mixed with substrate S1 and allowed to react overnight at 37°C. The control protein C1(DHFR) was mixed with substrate S1 and reacted simultaneously under the same conditions. Figure 1 shows the results of electrophoresis (15% polyacrylamide gel, Syber Green staining) of the sample solutions after the reaction.

[0054] In the sample after the reaction of P1(I-Bma I) with substrate S1, two distinct bands newly appeared around 700 bp and 800 bp (lane 1). In contrast, in the sample after the reaction of C1(DHFR) mixed with substrate S1 under the same conditions, the two bands that appeared in lane 1 did not appear (lane 2). These results indicate that I-Bma I recognized and cleaved the base sequence of substrate S1.

[0055] (Example 3) Evaluation test of cleavage activity of I-Bma I (2) (1) Preparation of enzyme protein Escherichia coli BL21 was transformed with the pET24a plasmid (pET24a::orf14) into which the I-Bma I(orf14) gene was inserted, and the transformed Escherichia coli (BL21+PET24a::orf14) was subjected to IPTG induction to express the protein. The culture solution of the expressed Escherichia coli was sonicated, and the soluble components were used as the target protein P1(I-Bma I) solution for the cleavage experiment. The restriction enzyme Eco RI was used as the control protein C2.

[0056] (2) Preparation of substrate S1044 (pMD20::orf14_subst0[420rc..741R]_ds64) S1044 (pMD20::orf14_subst0[420rc..741R]_ds64) was prepared as the substrate. Substrate S1044 was prepared by inserting orf14_subst0(tgacggtact taaggaataa gcatcggcta actccgtgcc agcagccgcg gtaatacgga ggat (SEQ ID NO: 7), a 64 bp basic substrate of I-Bma I, into a pMD20 vector, and then PCR amplifying the same vector using the following primer pair [420rc;741R] (conditions: 94°C for 2 minutes, (98°C for 10 seconds, 55°C for 10 seconds, 68°C for 30 seconds) x 25 cycles, 68°C for 4 minutes). Substrate S1044 was a linear double-stranded DNA with a length of 1044 bp.

[0057] Primer pairs [420rc; 741R] 420rc: 5'-GTCAGTGAGCGAGGAAGCGG-3' (SEQ ID NO: 10) 741R: 5'-CACGGAAATGTTGAATACTCATACTCTTCC-3' (SEQ ID NO: 9)

[0058] (3) Reaction of enzyme protein with substrate S1044 The P1(I-Bma I) prepared in (1) and (2) respectively was mixed with substrate S1044 and allowed to react by standing overnight at 37°C. Figure 2 shows the results of electrophoresis (1.2% agarose gel, Syber Green staining) of the sample solution after the reaction.

[0059] In the sample after the reaction of P1(I-Bma I) with substrate S1044, two distinct new bands appeared around 400 bp and 600 bp (lane 1). Uncleaved substrate S1044 appeared at the 1044 bp position. As a control, the sample after reacting a mixture of restriction enzyme Eco RI and substrate S1044 showed bands in positions similar to those in lane 1 (lane 2). The cleavage site of the restriction enzyme Eco RI is located approximately 30 bp downstream of the multiple cloning site (MCS) within S1044. From these findings, it was predicted that the DNA fragment after cleavage by Eco RI would be slightly shorter on the 741R side and slightly longer on the 420rc side compared to the DNA fragment after cleavage by I-Bma I of S1044. The electrophoresis results were as predicted, confirming that the two bands in lane 1 were substrate DNA fragments cleaved at the insertion site of orf14_subst0.

[0060] (Example 4) Analysis of the recognition sequence and cut shape when cutting the target sequence of I-Bma I (1) Preparation of sequencing samples In the electrophoresis of Example 3, gels were cut from the two bands around 400 bp and 600 bp that appeared in lane 1 to examine their base sequences. DNA was extracted from gel fragment X600 cut from the band around 600 bp and gel fragment X400 cut from the band around 400 bp in the electrophoresis diagram of Figure 2 using the electroelute method, concentrated using Miilipore Amicon, and prepared for sequencing.

[0061] (2) Sequence analysis of gel X400 (X2) The base sequence of gel X400 was sequenced using M13R (5'-CAGGAAACAGCTATGAC-3': Sequence ID No. 11) as a primer. Gel X400 was thought to be a DNA fragment of pMD20 from 420rc to near the MCS. The sequenced base sequence is shown in Figure 3. Of the base sequences in Figure 3, bases 51 to 80 were derived from pMD20. Bases 81 to 110 were derived from the substrate orf14_subst0, and were the first 30 bases of orf14_subst0 (orf14_subst0[1..30]). Bases from base 111 onwards were missing. The absence of bases from base 111 onwards indicates that the substrate sequence orf14_subst0 from base 31 onwards was cleaved by the protein.

[0062] The waveform data from the sequence analysis is shown in Figure 4. The data intensity of the sequences from the 111th position onward decreased significantly, indicating that a DNA break occurred.

[0063] The following is the cleavage subsequence orf14_subst0[1..30] obtained from sequence analysis of gel X400: 5'-tgacggtact taaggaataa gcatcggcta- 3' (SEQ ID NO: 13)

[0064] (3) Sequence analysis of gel X600 (X1) The base sequence of gel X600 was analyzed using 264R (5'-GCGCAACTGTTGGGAAGGGCG-3': Sequence ID No. 12) as a primer. Gel X600 was thought to be a DNA fragment from 741R of pMD20 to near the MCS. Sequences were performed in reverse (towards base position 1) from base position 264 of pMD20. The analyzed base sequence is shown in Figure 5. Of the base sequence, bases 51 to 141 were derived from pMD20, and bases 142 to 171 were the complementary strand of the substrate base sequence. The base sequence after base 172 was cleaved.

[0065] The waveform data from the sequence analysis is shown in Figure 6. The intensity of the data from position 172 onwards in the base sequence drops significantly, indicating that the sample was cut off at position 171.

[0066] From the results above, it was found that the DNA fragment recovered from gel X600 was orf14_subst0 [35..64] rc, a DNA fragment that was cut at a position 30 bases from the beginning of the complementary strand of orf14_subst0 [1..64] (Figure 7, rc: reverse complement).

[0067] The following is the cleavage subsequence orf14_subst0 [35..64]rc obtained from sequence analysis of gel X600: 3'-gcacgg tcgtcggcgc cattatgcct ccta- 5' (SEQ ID NO: 14)

[0068] (4) Shape of the cleavage site Figure 8A shows the combined results of sequence analysis using primer M13R (SEQ ID NO: 11) and primer 264R (SEQ ID NO: 12). The base sequence portions indicated by X2 (M13R->) and X1 (<-264R) correspond to the base sequences of the main strand and complementary strand obtained from the DNA sample extracted from the gel cut out from the band.

[0069] The Sanger sequencing method used for sequencing analysis terminates at the point where the complementary strand to the DNA strand extending from the analysis start primer is broken. Therefore, the cleavage site of orf14_subst0 (64 bases long, double-stranded) has the shape of a 3' overhang with a 4-base overhang, and the overhang was in the [31..34] region of orf14_subst0 (Figure 8B).

[0070] (Example 5) Recognition Sequence Refinement and Cleavage Test In Example 4, a 64 bp double-stranded DNA (orf14_subst0 [1..64]) was used as the cleavage substrate for I-Bma I, and cleavage activity analysis was performed to determine the cleavage site shape. In this example, the recognition sequence was refined.

[0071] We focused on the 20-base DNA sequence orf14_subst0 [23..42] (Figure 9) and analyzed whether or not it had I-Bma I cleavage activity.

[0072] A 20-base sequence orf14_subst0 _ds20 (5'-atcggctaactccgtgccag-3': Sequence ID No. 15) was inserted into the plasmid vector PMD20 using the TA cloning method. Blue / white selection was performed, and the plasmid with the target substrate fragment inserted was recovered from the white colonies.

[0073] Using a plasmid with the target substrate fragment inserted as a template, PCR was performed using the primer pair [620rc;741R] (94°C for 2 minutes, (98°C for 10 seconds, 55°C for 10 seconds, 68°C for 30 seconds) x 25 cycles, 68°C for 4 minutes) to produce linear double-stranded DNA containing orf14_subst0_ds20.

[0074] The base length of pMD20 [620rc; 741R]_ds20 was 1220 bp. Since it was prepared by TA cloning, the inserted 20-base DNA fragment was incorporated into the MCS of pMD20 in the opposite direction to that of Example 4. That is, the orientation of the incorporated DNA fragment was the same as that of the complementary strands of M13R and orf14_subst0_ds20.

[0075] Cleavage experiments were performed using pMD20 [620rc; 741R]_ds20 (hereinafter referred to as substrate S20). Escherichia coli BL21+pET24a::orf14 expressing I-Bma I was used, and I-Bma I was expressed by IPTG induction. The supernatant obtained by sonication of the culture medium expressing I-Bma I was used as protein (P1). A sample solution was prepared by mixing protein (P1) with substrate S20 to contain MgCl2 at a final concentration of 10 mM.

[0076] Figure 10 shows the results of electrophoresis after the above sample solution was incubated overnight. Novel bands appeared around 600 bp and 700 bp in lane 1. These novel bands indicate that the substrate pMD20 [620rc; 741R]_ds20 (length 1220 bp) was cleaved.

[0077] The above experiment demonstrated that even the 20 bp length orf14_subst0 [23..42] sequence is recognized by I-Bma I and becomes a target (substrate) for P1 cleavage. In other words, the 20 bp base sequence (atcggctaactccgtgccag: Sequence ID 3) was identified as the recognition sequence for I-Bma I.

[0078] (Example 6) Cleavage experiment of I-Bma I against the E.coli_rrn16S gene (1) Production of protein P1(I-Bma I) In the same manner as in Example 2, P1(I-Bma I) was produced in a cell-free protein synthesis system using plasmid pET24a::orf14 as the synthesis template.

[0079] (2) Preparation of substrate S2 (Ecoli_rrn16S [17..1313]) Escherichia coli DH5α (commercial product) was disrupted with Triton-X and DNA was extracted. The DNA sequence from position 17 to 1313 of the Escherichia coli rrn16s gene (total length 1530 bases) was amplified by PCR using the following primer pair [17F;1313R] (conditions: 94°C for 2 minutes, (98°C for 10 seconds, 55°C for 10 seconds, 68°C for 30 seconds) x 25 cycles, 68°C for 4 minutes) to prepare substrate S2 (Ecoli_rrn16S [17..1313]). Substrate S2 was a linear double-stranded DNA with a length of 1296 bp.

[0080] Primer pair [17F;1313R] 17F: 5'-agattgaacgctggcggc-3' (SEQ ID NO: 16) 1313R: 5'-cgagttgcagactccaat-3' (SEQ ID NO: 17)

[0081] (3) Reaction of P1(I-Bma I) and substrate S2 The P1(I-Bma I) and substrate S2 prepared in (1) and (2) respectively were mixed and allowed to react overnight at 37°C. Figure 11 shows the results of electrophoresis (15% polyacrylamide gel, Syber Green staining) of the reaction sample solution.

[0082] In the sample after the reaction of P1(I-Bma I) with substrate S2, two distinct new bands appeared around 700 bp and 600 bp (lane 1, black arrows). In contrast, in the sample after reacting substrate S2 alone under the same conditions, the two bands that appeared in lane 1 did not appear (lane 2). These results indicate that I-Bma I cleaved the substrate Ecoli rrn16S [17..1313] (length 1296 bp) into two DNA fragments.

[0083] This invention can be used in the field of research reagents and the manufacture of antimicrobial agents in the field of genetic engineering. All publications, patents, and patent applications cited herein are incorporated herein by reference in their entirety.

Claims

1. A homing endonuclease consisting of one of the following proteins (a) to (c): (a) A protein consisting of the amino acid sequence shown in SEQ ID NO: 1 (b) A protein consisting of an amino acid sequence in which one or more amino acids are added, deleted, or substituted in the amino acid sequence shown in SEQ ID NO: 1, and which has the activity to recognize and cleave a 20-base sequence including at least 15 consecutive bases in the base sequence: atcggctaactccgtgccag (SEQ ID NO: 3) (c) A protein consisting of an amino acid sequence having 90% or more sequence identity with the amino acid sequence shown in SEQ ID NO: 1, and which has the activity to recognize and cleave a 20-base sequence including at least 15 consecutive bases in the base sequence: atcggctaactccgtgccag (SEQ ID NO: 3) 2. A gene encoding the homing endonuclease described in claim 1.

3. A gene encoding a homing endonuclease consisting of one of the following polynucleotides: (d) A polynucleotide consisting of the nucleotide sequence shown in SEQ ID NO:

2. (e) A polynucleotide encoding a protein consisting of a nucleotide sequence having 90% or more sequence identity with the nucleotide sequence shown in SEQ ID NO: 2, and having the activity to recognize and cleave a 20-nucleotide sequence including at least 15 consecutive nucleotides in the nucleotide sequence: atcggctaactccgtgccag (SEQ ID NO: 3). (f) A polynucleotide encoding a protein that hybridizes under stringent conditions with a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 2, and has the activity to recognize and cleave a 20-nucleotide sequence including at least 15 consecutive nucleotides in the nucleotide sequence: atcggctaactccgtgccag (SEQ ID NO: 3).

4. A vector comprising the gene described in claim 2 or 3.

5. The vector according to claim 4, wherein the vector is a plasmid or a bacteriophage.

6. A transformer comprising the vector described in claim 4.

7. A method for producing a homing endonuclease, characterized by culturing the transformant described in claim 6 and collecting the protein described in claim 1 from the resulting culture.

8. An antimicrobial agent containing the homing endonuclease described in claim 1 as an active ingredient.

9. The antibacterial agent according to claim 8, in the form of a bacteriophage formulation.